Cambridge Healthtech Institute Training Seminars offer real-life case studies, problems encountered and solutions applied, along with extensive coverage of the academic theory and background. Each Training Seminar offers a mix of formal lecture and interactive discussions and activities to maximize the learning experience. These Training Seminars are led by experienced instructors who will focus on content applicable to your current research and provide important guidance for those new to their fields.
TS10B: Introduction to Cancer Immunotherapy Discovery and Development
WEDNESDAY, September 2 - THURSDAY, September 3
DAY 1: WEDNESDAY
8:40 am - 6:00 pm Seminar Sessions
12:30 - 1:30 Lunch Provided
6:00 - 7:15 Taste of New England Networking Reception in the Exhibit Hall with Poster Viewing
DAY 2: THURSDAY
8:30 am - 12:30 pm Seminar Sessions
Exhibit Hall Refreshment Breaks also provided.
Instructor:
Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, Inc., a Miltenyi Biotec Company
This course is designed for scientists and biotechnology professionals new to the realm of cancer immunotherapy, or those interested in a broad yet detailed perspective of this field. The 1.5-day instruction comprises an overview of the currently used approaches, and incorporates numerous examples for technology discovery and development, with an emphasis on new trends. Immune checkpoint inhibitors and CAR T therapies have recently gained regulatory approval in the US and the EU. TILs- and TCR -based therapies, NK therapies, as well as cancer vaccines are areas of great promise, and may yield future breakthroughs. Advances in high throughput sequencing and immunogenomics aid in identifying novel tumor antigens, building better effector molecules and vaccines, and predicting treatment outcomes, for both personalized and universal immunotherapy.
Topics to Be Discussed:
- Historical Perspective
- Primer to Immunotherapy
- Monoclonal Antibodies
- Checkpoint Blockade Inhibitors
- TILs, TCRs and other T-cell Based Therapeutics
- CARs
- Gene Delivery for Cell-Based Therapies
- Tumor Vaccines
- Oncolytic Viruses
- Combination Therapies
- Cancer Genomics and Immunogenomics
- Clinical Progress to Date and Future Directions
Instructor:
Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, Inc., a Miltenyi Biotec Company
Dina Schneider, Ph.D., is a scientist and an inventor with over-15 years of experience in academia and industry. Dr. Schneider earned her Ph.D. from Michigan State University, and completed her postdoctoral training at the University of Michigan. Her academic career spanned diverse areas of interest, including cellular and molecular immunology, immunotoxicology, inflammation, and molecular biology. In 2011, Dr. Schneider transitioned to industry, where she contributed to numerous projects in synthetic immunology, immunotherapy, and chimeric antigen receptor (CAR) T cell-based therapy. Dr. Schneider leads the Translational Research group at Lentigen Technology, Inc., a Miltenyi Biotec Company, in Gaithersburg, MD. Her group is focused on pre-clinical development of novel CAR-based therapies targeting hematologic malignancies as well as solid tumors, and on the implementation of CliniMACS Prodigy® clinical platform for preparation of cell-based therapeutics. Her recent work includes the development of novel CAR therapies, three of which are now in clinical trials.
WHAT IS A TRAINING SEMINAR?
Each CHI Training Seminar offers 1.5 days of instruction, refreshment breaks, exhibit hall functions, and lunch for all registered attendees on the full day of the class. Each person registered for the Training Seminar will be provided with a hard copy handbook for the Training Seminar in which they are registered. A limited number of additional handbooks may be available for other delegates. CHI encourages track hopping between conference programs, and we ask that Training Seminars not be disturbed once they have begun. We ask that attendees commit to attending the entire 1.5-day training, and not engage in track hopping once the class has started.
